Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Nrx Pharmaceuticals, Inc. (NRXP) since 2017 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Nrx Pharmaceuticals, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1719406.
Total stock buying since 2017: $6,748,261.
Total stock sales since 2017: $2,524,086.
Total stock option exercises since 2017: $234,432.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2024 | 40,000 | $46,800 | 0 | $0 | 0 | $0 |
| 2023 | 405,000 | $128,760 | 0 | $0 | 0 | $0 |
| 2022 | 628,087 | $6,347,701 | 1,418,683 | $1,299,365 | 0 | $0 |
| 2021 | 0 | $0 | 73,715 | $912,403 | 140,989 | $234,432 |
| 2020 | 0 | $0 | 29,464 | $312,318 | 0 | $0 |
| 2018 | 0 | $0 | 1,500,000 | $0 | 0 | $0 |
| 2017 | 22,500 | $225,000 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2024-12 | 40,000 | $46,800 | 0 | $0 | 0 | $0 |
| 2023-08 | 405,000 | $128,760 | 0 | $0 | 0 | $0 |
| 2022-11 | 528,087 | $547,701 | 188,908 | $204,479 | 0 | $0 |
| 2022-07 | 0 | $0 | 784,063 | $791,119 | 0 | $0 |
| 2022-06 | 100,000 | $5,800,000 | 445,712 | $303,767 | 0 | $0 |
| 2021-09 | 0 | $0 | 40,000 | $470,400 | 31,584 | $96,962 |
| 2021-08 | 0 | $0 | 33,715 | $442,003 | 109,405 | $137,470 |
| 2020-03 | 0 | $0 | 29,464 | $312,318 | 0 | $0 |
| 2018-11 | 0 | $0 | 1,500,000 | $0 | 0 | $0 |
| 2017-11 | 22,500 | $225,000 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-12-17 | Javitt Jonathan C (Chairman and Chief Scientist) | Buy | 40,000 | 1.17 | 46,800 |
| 2023-08-30 | Gorovitz Aaron | Buy | 35,000 | .32 | 11,200 |
| 2023-08-30 | Hurvitz Chaim | Buy | 70,000 | .29 | 20,160 |
| 2023-08-23 | Javitt Jonathan C (Chief Scientist) | Buy | 100,000 | .33 | 33,000 |
| 2023-08-22 | Javitt Jonathan C (Chief Scientist) | Buy | 200,000 | .32 | 64,400 |
| 2022-11-30 | Javitt Daniel C. (10% Owner) | Sale | 8,441 | 1.50 | 12,703 |
| 2022-11-29 | Javitt Daniel C. (10% Owner) | Sale | 13,730 | 1.50 | 20,649 |
| 2022-11-28 | Flynn Patrick John | Buy | 11,750 | 1.25 | 14,664 |
| 2022-11-25 | Van Voorhees Seth (CHIEF FINANCIAL OFFICER) | Buy | 16,337 | 1.11 | 18,134 |
| 2022-11-18 | Hurvitz Chaim | Buy | 40,408 | 1.10 | 44,448 |
| 2022-11-17 | Javitt Daniel C. (10% Owner) | Sale | 33,018 | 1.05 | 34,734 |
| 2022-11-17 | Hurvitz Chaim | Buy | 171,780 | 1.08 | 185,522 |
| 2022-11-16 | Javitt Daniel C. (10% Owner) | Sale | 133,719 | 1.02 | 136,393 |
| 2022-11-16 | Hurvitz Chaim | Buy | 287,812 | .99 | 284,933 |
| 2022-07-29 | Javitt Daniel C. (10% Owner) | Sale | 784,063 | 1.01 | 791,119 |
| 2022-06-07 | Javitt Daniel C. (10% Owner) | Sale | 86,459 | .65 | 55,852 |
| 2022-06-06 | Javitt Daniel C. (10% Owner) | Sale | 115,657 | .67 | 76,911 |
| 2022-06-03 | Javitt Daniel C. (10% Owner) | Sale | 243,596 | .70 | 171,004 |
| 2022-06-01 | Javitt Jonathan C (Chief Scientist) | Buy | 100,000 | 58.00 | 5,800,000 |
| 2021-09-15 | Besthof Robert (Chief Comm. & Patient Officer) | Sale | 40,000 | 11.76 | 470,400 |
| 2021-09-02 | Daigneault Alessandra (General Counsel & Secretary) | Option Ex | 31,584 | 3.07 | 96,962 |
| 2021-08-26 | Mcmaster Herbert Raymond | Option Ex | 18,300 | 2.22 | 40,626 |
| 2021-08-23 | Daigneault Alessandra (General Counsel & Secretary) | Sale | 33,715 | 13.11 | 442,003 |
| 2021-08-19 | Daigneault Alessandra (General Counsel & Secretary) | Option Ex | 27,395 | 3.07 | 84,102 |
| 2021-08-16 | Besthof Robert (Chief Comm. & Patient Officer) | Option Ex | 63,710 | .20 | 12,742 |
| 2020-03-13 | Polar Asset Management Partners Inc. (10% Owner) | Sale | 29,464 | 10.60 | 312,318 |
| 2018-11-20 | Big Rock Partners Sponsor, Llc (President and CEO) | Sale | 1,500,000 | .00 | 0 |
| 2017-11-29 | Big Rock Partners Sponsor, Llc | Buy | 22,500 | 10.00 | 225,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of NRXP listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Nrx Pharmaceuticals, Inc. (symbol NRXP, CIK number 1719406) see the Securities and Exchange Commission (SEC) website.